NCT04689828 2026-02-20
PSMAfore
Novartis
Phase 3 Active not recruiting
Clinical Trials
24 trialsNCT04176497 2025-12-11
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT05547386 2025-07-18
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 3 Completed
NCT04750473 2025-01-17
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
Emory University
Phase 1 Completed
NCT04716725 2024-10-16
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Active not recruiting
NCT03276572 2024-06-13
Phase I Trial of 225Ac-J591 in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Completed
NCT03822871 2024-03-21
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Cancer Targeted Technology
Phase 1 Completed
NCT04264208 2024-02-01
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Stanford University
Phase 2 Terminated
NCT03949517 2024-01-30
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Stanford University
Phase 1/2 Completed
NCT03396874 2023-11-03
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
University of Michigan
Phase 2 Completed
NCT04614363 2023-08-28
68 Ga-PSMA for High Risk Prostate Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT04179968 2023-03-20
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02678351 2022-03-04
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Stanford University
Phase 2/3 Completed
NCT02673151 2022-01-13
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Stanford University
Phase 2/3 Completed
NCT03689582 2022-01-05
Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03353740 2021-10-21
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
University of California, San Francisco
Phase 3 Completed
NCT03545165 2021-08-24
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT03803475 2021-08-24
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
University of California, San Francisco
Phase 3 Completed
NCT03463889 2021-06-29
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02611882 2020-12-22
PSMA PET
University of California, San Francisco
Phase 2 Completed
NCT02919111 2020-12-10
PSMA PreRP
University of California, San Francisco
Phase 2/3 Completed
NCT03675451 2020-10-14
PSMA Imaging of Localized Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Completed
NCT02488070 2018-03-20
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Stanford University
Phase 1/2 Completed